| ID Source | ID |
|---|---|
| PubMed CID | 11237985 |
| CHEMBL ID | 2103858 |
| SCHEMBL ID | 731063 |
| MeSH ID | M0507267 |
| Synonym |
|---|
| 860174-12-5 |
| naronapride (usan/inn) |
| D09933 |
| unii-058896b00b |
| ati-7505 |
| naronapride [usan:inn] |
| naronapride |
| (3r)-1-azabicyclo(2.2.2)oct-3-yl 6-((3s,4r)-4-((4-amino-5-chloro-2-methoxybenzoyl)amino)-3-methoxy-1-piperidinyl)hexanoate |
| 1-piperidinehexanoic acid, 4-((4-amino-5-chloro-2-methoxybenzoyl)amino)-3-methoxy-, (3r)-1-azabicyclo(2.2.2)oct-3-yl ester, (3s,4r)- |
| ati 7505 |
| ati7505 |
| 058896b00b , |
| naronapride [usan] |
| 1-piperidinehexanoic acid, 4-((4-amino-5-chloro-2-methoxybenzoyl)amino)-3-methoxy-, 1-azabicyclo(2.2.2)oct-3-yl ester, (3s,4r)- |
| naronapride [inn] |
| naronapride [who-dd] |
| (3r)-1-azabicyclo(2.2.2)oct-3-yl 6-((3s,4r)-4-((4-amino-5-chloro-2- methoxybenzoyl)amino)-3-methoxypiperidin-1-yl)hexanoate |
| CHEMBL2103858 |
| SCHEMBL731063 |
| DB05542 |
| 860174-12-5 (free base) |
| naronapride free base |
| (r)-quinuclidin-3-yl 6-((3s,4r)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate |
| Q27236096 |
| DTXSID401006590 |
| 4-amino-n-(1-{6-[(1-azabicyclo[2.2.2]octan-3-yl)oxy]-6-oxohexyl}-3-methoxypiperidin-4-yl)-5-chloro-2-methoxybenzene-1-carboximidic acid |
| CS-0083508 |
| HY-121826 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 3 (60.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (20.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Effect of ATI-7505 on Gastric Emptying and Small Bowel and Colonic Transit in Healthy Volunteers [NCT01094821] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-Controlled, 58 Day, Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome [NCT00630370] | Phase 2 | 6 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
| A Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation [NCT00501241] | Phase 2 | 214 participants (Anticipated) | Interventional | 2007-07-31 | Terminated | ||
| Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis [NCT05621811] | Phase 2 | 320 participants (Anticipated) | Interventional | 2023-01-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||